Drug intelligence / Profile preview

JRF105

Development stage: Unknown
Lead developer: Shenzhen Jinruijiye Biotechnology
Modality: Small Molecules

Overview

JRF105 is a small molecule Janus kinase (JAK) inhibitor currently under development by Shenzhen Jinruijiye Biotechnology. It is being investigated for the treatment of solid tumors and brain edema. As a JAK inhibitor, JRF105 targets the JAK-STAT signaling pathway, which plays a critical role in cell growth, survival, and immune response; dysregulation of this pathway is frequently associated with oncogenesis and inflammatory processes. The drug is currently in Phase 1 clinical trials, representing part of the company's pipeline focused on addressing brain-related pathologies and oncology.

Targets

JAK (Janus kinase family)

Beyond the preview

Go deeper on JRF105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JRF105.

Explore the full profile